EXAMINER'S AMENDMENT

~~**Amendments to the Claims:**~~

1. (Currently Amended) A compound of formula (I)



R is halogen, C_{1-4} alkyl, cyano, C_{1-4} alkoxy, trifluoromethyl or trifluoromethoxy;

R_1 is hydrogen, halogen, C_{3-7}cycloalkyl, hydroxy, nitro, cyano or C_{1-4} alkyl optionally substituted by halogen, cyano or C_{1-4} alkoxy;

R_2 is hydrogen or C_{1-4} alkyl;

R_3 and R_4 independently are hydrogen, cyano, C_{1-4} alkyl or R_3 together with R_4 and the carbon to which they are bonded form a C_{3-7} cycloalkyl;

R_5 is trifluoromethyl, $S(O)_t$ C $_{1-4}$ alkyl, C_{1-4} alkyl, C_{1-4} alkoxy, trifluoromethoxy, halogen or cyano;

R_6 is hydrogen or $(CH_2)rR_7$;

R_7 is hydrogen, C_{3-7} cycloalkyl, $NH(C_{1-4}alkylOC_{1-4}alkoxy)$, $NH(C_{1-4}alkyl)$, $N(C_{1-4}alkyl)_2$, $OC(O)NR_9R_8$, $NR_8C(O)[[5]]R_9$ or $C(O)NR_9R_8$;

R_9 and R_8 independently are hydrogen, C_{1-4} alkyl or C_{3-7} cycloalkyl;

m is ~~zero or an integer from~~ 1 ~~to 4~~;

n is 1;

p is zero or an integer from 1 to 3;

q is an integer from 1 to 3;

r is an integer from 1 to 4;

t is 0 , 1 or 2 ;

~~provided that when m is 0, p is 2, q , r and n is 1, R_1, R_2,R_3, R_4, R_5 and R_7 are hydrogen and R is chlorine, then R_5 is not iodine;~~

or a pharmaceutically acceptable salt ~~or solvate~~ thereof.

2 (Previously presented) A compound as claimed in claim 1 wherein R is halogen, cyano, trifluoromethyl or a C_{1-4} alkyl and p is 0 or an integer from 1 to 2.

3. (Previously presented) A compound as claimed in claim 1 wherein R_5 is trifluoromethyl, cyano, methyl or halogen and q is an integer from 1 to 2.

4. (Currently Amended) A compound as claimed in claim 1 wherein R_6 is hydrogen or $(CH_2)_rR_7$ in which r is 1 or 2 and R_7 is hydrogen, cyclopropyl, C(O)N(C_{1-4} alkyl)$_2$, or C(O)NH(C_{1-4} alkyl) ~~or C_{1-4} alkoxy~~.

5. (Currently Amended) A compound as claimed in claim 1 wherein R is C_{1-4} alkyl , halogen, trifluoromethyl or cyano; R_1 is hydrogen, methyl, ethyl or halogen, R_2 is a methyl or hydrogen, R_3 and R_4 are independently hydrogen or methyl, R_5 is trifluoromethyl, cyano, methyl, chlorine, bromine or fluorine, R_6 is hydrogen, methyl, ethyl methylcyclopropyl ~~$(CH_2)_2OCH_3$~~ or $CH_2C(O)N(CH_3)_2$, p is 0 or an integer from 1 to 2, m is ~~0 or~~ 1, n is 1, and q is 1 or 2.

/CC/

~~6.~~ (Cancelled).

~~7.~~ (Previously presented) A compound selected from:

N-(3,5-Dichlorobenzyl)-2-[4-(4-fluorophenyl)-piperidin-4-yl]-N-methyl-acetamide;

N-(3,5-Dichlorobenzyl)-2-[3-fluoro-4-(4-fluorophenyl)-piperidin-4-yl]-N-methyl-acetamide ;

~~4-(4-Fluorophenyl)-piperidine-4-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide;~~

~~4-(4-Chlorophenyl)-piperidine-4-carboxylic acid, (3,5-bis-trifluoromethyl-benzyl)-methylamide;~~

~~4-(4-Fluorophenyl)-piperidine-4-carboxylic acid (3,5-dichloro-benzyl)-methylamide;~~

N-(3,5-Bis-trifluoromethyl)-benzyl-2-[(4-fluoro-2-methyl-phenyl)-piperidin-4-yl]-N-methyl-acetamide;

N-(3,5-Dichlorobenzyl)-2-[4-(4-fluoro-2-methyl-phenyl)-piperidin-4-yl]-N-methyl-acetamide;

N-(3,5-Bis-trifluoromethyl-benzyl)-2-[4-(4-fluorophenyl)-azepin-4-yl]-N-methyl-acetamide;

N-(3,5-Bis-trifluoromethyl-benzyl)-2-[4-(4-fluoro-2-methyl-phenyl)-azepin-4-yl]-N-methyl-acetamide;

N-(3,5-Dichlorobenzyl)-2-[4-(4-fluoro-2-methyl-phenyl)-azepin-4-yl]-N-methyl-acetamide;

N-(3,5-Bis-trifluoromethyl-benzyl)-2-[3-fluoro-4-(4-fluoro-2-methyl-phenyl)-azepin-4-yl]-N-methyl-acetamide;

N-(3,5-Dichlorobenzyl)-2-[3-fluoro-4-(4-fluoro-2-methyl-phenyl)-azepin-4-yl]-N-methyl-acetamide;

N-(3,5-Dichlorobenzyl)-2-[3-fluoro-4-(4-fluoro-2-methyl-phenyl)-azepin-4-yl]-N-methyl-acetamide;

N-(3,5-Bis-trifluoromethyl-benzyl)-2-[3-fluoro-4-(4-fluoro-2-methyl-phenyl)-azepin-4-yl]-N-methyl-acetamide;

N-(3,5-Dibromobenzyl)-2-[4-(4-fluorophenyl)-piperidin-4-yl]-N-methyl-acetamide;

N-(3,5-Dibromo-benzyl)-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide;

N-(3,5-Dibromobenzyl)-2-(4-phenyl-piperidin-4-yl)-N-methyl-acetamide;

N-(3,5-Dibromo-benzyl)-2-(4-phenyl-1-methyl-piperidin-4-yl)-N-methyl-acetamide;

N-[1-(3,5-Dichloro-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-piperidin-4-yl]-N-methyl-acetamide;

N-[1-(3,5-Dichloro-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide;

N-[1-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-piperidin-4-yl]-N-methyl-acetamide;

N-[1-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide;

N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-piperidin-4-yl]-N-methyl-acetamide;

N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide;

N-[1-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-2-(4-phenyl-piperidin-4-yl)-N-methyl-acetamide;

N-[1-(3,5- Bis-trifluoromethyl-phenyl)-ethyl]-2-(4-phenyl-1-methyl-piperidin-4-yl)-N-methyl-acetamide;

N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-(4-phenyl-piperidin-4-yl)-N-methyl-acetamide;

N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-(4-phenyl-1-methyl-piperidin-4-yl)-N-methyl-acetamide;

N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-piperidin-4-yl]-N-methyl-acetamide;

N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide;

~~*N*-[(3,5-Dichlorophenyl)methyl]-2-[4-(4-fluoro-2-methylphenyl)-1-[2-(methyloxy)ethyl]-4-piperidinyl]-*N*-methylacetamide;~~

N-{1-[3,5-Bis(trifluoromethyl)phenyl]ethyl}-2-[4-(4-fluoro-2-methylphenyl)-4-piperidinyl]-*N*-methylacetamide;

N-[(3,5-Dibromophenyl)methyl]-2-[4-(4-fluoro-2-methylphenyl)-4-piperidinyl]-*N*-methylacetamide;

N-[[3,5-Bis(trifluoromethyl)phenyl]methyl]-2-[4-(4-fluoro-2-methylphenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

N-[(3,5-Dichlorophenyl)methyl]-2-[4-(4-fluoro-2-methylphenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

N-[[3,5-Bis(trifluoromethyl)phenyl]methyl]-2-[4-(4-fluoro-2-methylphenyl)-4-piperidinyl]acetamide;

N-[[3,5-Bis(trifluoromethyl)phenyl]methyl]-2-[4-(4-fluoro-2-methylphenyl)-1-methyl-4-piperidinyl]acetamide;

N-[(3,5-Dibromophenyl)methyl]-2-[4-(4-fluoro-2-methylphenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

N-[(3,5-Dibromophenyl)methyl]-*N*-methyl-2-[4-(2-methylphenyl)-4-piperidinyl]acetamide;

N-[(3,5-Dibromophenyl)methyl]-*N*-methyl-2-[1-methyl-4-(2-methylphenyl)-4-piperidinyl]acetamide;

N-[(3,5-Dichlorophenyl)methyl]-2-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

N-[[3,5-Bis(trifluoromethyl)phenyl]methyl]-2-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

N-[1-(3,5-Dibromophenyl)-1-methylethyl]-2-[4-(4-fluorophenyl)-4-piperidinyl]-*N*-methylacetamide;

N-[1-(3,5-Dibromophenyl)-1-methylethyl]-2-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

N-[1-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-piperidin-4-yl]-N-methyl-acetamide ;

N-[1-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide;

2-[1-(Cyclopropylmethyl)-4-(4-fluorophenyl)-4-piperidinyl]-*N*-[(3,5-dibromophenyl)methyl]-*N*-methylacetamide;

2-[4-{2-[[(3,5-Dibromophenyl)methyl](methyl)amino]-2-oxoethyl}-4-(4-fluorophenyl)-1-piperidinyl]-*N*,*N*-dimethylacetamide;

N-[(3,5-Dibromophenyl)methyl]-2-[1-ethyl-4-(4-fluorophenyl)-4-piperidinyl]-*N*-methylacetamide;

N-{1-[3,5-Bis(trifluoromethyl)phenyl]ethyl}-2-[4-(4-fluorophenyl)hexahydro-1*H*-azepin-4-yl]-*N*-methylacetamide;

N-{1-[3,5-Bis(trifluoromethyl)phenyl]ethyl}-2-[4-(4-fluorophenyl)-1-methylhexahydro-1*H*-azepin-4-yl]-*N*-methylacetamide;

N-[(3,5-Dibromophenyl)methyl]-2-[4-(4-fluorophenyl)hexahydro-1*H*-azepin-4-yl]-*N*-methylacetamide;

N-[(3,5-Dibromophenyl)methyl]-2-[4-(4-fluorophenyl)-1-methylhexahydro-1*H*-azepin-4-yl]-*N*-methylacetamide;

N-[(3-Bromo-5-cyanophenyl)methyl]-2-[4-(4-fluorophenyl)-4-piperidinyl]-*N*-methylacetamide;

N-[(3-Bromo-5-cyanophenyl)methyl]-2-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

N-[(3,5-Dibromophenyl)methyl]-*N*-methyl-2-{4-[3-(trifluoromethyl)phenyl]-4-piperidinyl}acetamide;

N-[(3,5-Dibromophenyl)methyl]-*N*-methyl-2-{1-methyl-4-[3-(trifluoromethyl)phenyl]-4-piperidinyl}acetamide;

N-[(3,5-Dibromophenyl)methyl]-2-[4-(3,4-dimethylphenyl)-4-piperidinyl]-*N*-methylacetamide;

N-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(3-fluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

N-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(4-fluoro-3-methylphenyl)-4-piperidinyl]-*N*-methylacetamide;

N-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(4-fluoro-3-methylphenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

2-[4-(3-Chlorophenyl)-4-piperidinyl]-*N*-[1-(3,5-dibromophenyl)ethyl]-*N*-methylacetamide;

N-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(3,4-difluorophenyl)-4-piperidinyl]-*N*-methylacetamide;

N-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(3,4-difluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

N-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(3-fluorophenyl)-4-piperidinyl]-*N*-methylacetamide ;

N-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(3-fluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

N-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(4-fluoro-3-methylphenyl)-4-piperidinyl]-*N*-methylacetamide;

N-[1-(3,5-Dibromophenyl)ethyl]-2-[4-(4-fluoro-3-methylphenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

2-[4-(3-Chlorophenyl)-4-piperidinyl]-*N*-[1-(3,5-dibromophenyl)ethyl]-*N*-methylacetamide;

2-[4-(3-Chlorophenyl)-1-methyl-4-piperidinyl]-*N*-[1-(3,5-dibromophenyl)ethyl]-*N*-methylacetamide;

2-[4-(3-Chlorophenyl)-4-piperidinyl]-*N*-[1-(3,5-dichlorophenyl)ethyl]-*N*-methylacetamide;

2-[4-(3-Chlorophenyl)-1-methyl-4-piperidinyl]-*N*-[1-(3,5-dichlorophenyl)ethyl]-*N*-methylacetamide;

2-[4-(3-Chlorophenyl)-4-piperidinyl]-*N*-[(3,5-dibromophenyl)methyl]-*N*-methylacetamide;

N-[1-(3,5-Dichlorophenyl)ethyl]-2-[4-(4-fluoro-3-methylphenyl)-4-piperidinyl]-*N*-methylacetamide;

N-[(3,5-Dibromophenyl)methyl]-2-[4-(4-fluoro-3-methylphenyl)-4-piperidinyl]-*N*-methylacetamide;

N-[(3,5-Dibromophenyl)methyl]-2-[4-(4-fluoro-3-methylphenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide ;

N-[(3,5-Dibromophenyl)methyl]-2-[4-(3-fluorophenyl)-4-piperidinyl]-*N*-methylacetamide;

N-[(3,5-Dibromophenyl)methyl]-2-[4-(3-fluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

N-[(3,5-Dibromophenyl)methyl]-2-[4-(3,4-difluorophenyl)-4-piperidinyl]-*N*-methylacetamide;

N-[(3,5-Dibromophenyl)methyl]-2-[4-(3,4-difluorophenyl)-1-methyl-4-piperidinyl]-*N*-methylacetamide;

2-[4-(4-Cyanophenyl)-4-piperidinyl]-*N*-[1-(3,5-dibromophenyl)ethyl]-*N*-methylacetamide;

diastereoisomers or enantiomers thereof and pharmaceutically acceptable salts thereof.

8. (Previously presented) A compound selected from

[N-(3,5-Dibromo-benzyl)-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide;

N-[1-(*S*)-1-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide;

N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide (enantiomer 1);

N-[1-(3,5-Dibromo-phenyl)-ethyl]-2-(1-methyl-4-phenyl-piperidin-4-yl)-N-methyl-acetamide (enantiomer 1);

N-[1-(3,5-Dichloro-phenyl)-ethyl]-2-[4-(4-fluoro-phenyl)-1-methyl-piperidin-4-yl]-N-methyl-acetamide (enantiomer 1);

and pharmaceutically acceptable salts thereof.

11
~~9.~~ (Previously presented) A process (A) for the preparation of a compound as claimed in claim 1 which comprises reacting an activated derivative of the carboxylic acid of formula (II) wherein R_6 is a nitrogen protecting group or (CH2)rR_7 , with amine (III)



(II)



(III)

wherein R_2 is hydrogen, C_{1-4} alkyl or a nitrogen protecting group, followed where necessary by removal of any nitrogen protecting group.

10-12. (Canceled)

10
~~13.~~ (Previously presented) A pharmaceutical composition comprising a compound as claimed in claim 1 in admixture with one or more pharmaceutically acceptable carriers or excipients.

14. (Canceled)

8
~~15.~~ (Previously presented) A compound as claimed in claim 1 wherein R is fluorine or chlorine, cyano, trifluoromethyl or methyl and p is 0 or an integer from 1 to 2.

9
~~16.~~ (Currently Amended) A compound as claimed in claim 1 wherein R is C_{1-4} alkyl , chlorine or fluorine, trifluoromethyl or cyano; R_1 is hydrogen, methyl, ethyl or fluorine, R_2 is a methyl or hydrogen, R_3 and R_4 are independently hydrogen or methyl, R_5 is trifluoromethyl, cyano, methyl, chlorine, bromine or fluorine, R_6 is hydrogen, methyl, ethyl methylcyclopropyl $(CH_2)_2OCH_3$ or $CH_2C(O)N(CH_3)_2$, p is 0 or an integer from 1 to 2, m is ~~0 or~~ 1, n is 1, and q is 1 or 2.

12
~~17.~~ (Previously presented) A process (B) for the preparation of a compound as claimed in claim 1 wherein R_2 is C $_{1-4}$ alkyl comprising reacting a compound of formula(Ia), with (C $_{1-4}$ alkyl)L wherein L is a suitable leaving group selected from iodine, bromine



(Ia).

18. (Withdrawn) A method for the treatment of a condition mediated by a tachykinin and/or selective inhibition of serotonin reuptake transporter protein in a mammal in need thereof, comprising administering an effective amount of a compound as claimed in claim 1.

/CC/

19. (Withdrawn) The method as claimed in claim 18, wherein said tachykinin is substance P.

20. (Withdrawn) The method as claimed in claim 18, wherein said mammal is man.